Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ependymoma 1Disease Progression 1

Interventions

vandetanib 2Lenalidomide 2Bortezomib 2marizomib 1enzastaurin 1carotuximab 1Tamoxifen 1Steroids 1Multiparametric Magnetic Resonance Imaging 1Irinotecan 1Dexamethasone 1Carboplatin 1Calcium Dobesilate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Disease Progression × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡